

DAFTAR PUSTAKA

- Abdin, A.A., Hassanien, M.A., Ibrahim, E.A., El-Noeman, S.E.D.A.A., 2010. Modulating effect of atorvastatin on paraoxonase 1 activity in type 2 diabetic Egyptian patients with or without nephropathy. *J Diabetes Complications*. 24(5):325–333. doi: 10.1016/j.jdiacomp.2009.01.005.
- Abdollahzad, H., Eghtesadi, S., Nourmohammadi, I., Khadem-Ansari, M., Nejad-Gashti, H., Esmailzadeh, A., 2009. Effect of Vitamin C Supplementation on Oxidative Stress and Lipid Profiles in Hemodialysis Patients. *Int. J. Vitam. Nutr. Res.* 79: 281–287.
- Acosta-Ochoa, I., Bustamante-Munguira, J., Mendiluce-Herrero, A., Bustamante-Bustamante, J., Coca-Rojo, A., 2019. Impact on Outcomes across KDIGO-2012 AKI Criteria According to Baseline Renal Function. *J. Clin. Med.* 28(8 Pt 9): 1323.
- Arnadottir, M., Brattström, L., Simonsen, O., Thysell, H., Hultberg, B., Andersson, A., Nilsson-Ehle, P., 1993. The effect of high-dose pyridoxine and folic acid supplementation on serum lipid and plasma homocysteine concentrations in dialysis patients. *Clin Nephrol.* 40(4):236-40. PMID: 8261682.
- Ascorb, I., Jialal, C.J., Fuller. 1995. Effect of vitamin E, vitamin C and beta-carotene on LDL oxidation and atherosclerosis. *Can J Cardiol*, 11: pp. 97G-103G.
- Ashor A.W., Siervo M., Van Der Velde F., Willis N.D., Mathers J.C., 2015. Systematic review and meta-analysis of randomised controlled trials testing the effects of vitamin C supplementation on blood lipids. *Clinical Nutrition.* 35(3):P626-637. DOI : [10.1016/j.clnu.2015.05.021](https://doi.org/10.1016/j.clnu.2015.05.021).
- Attman, P.O., Samuelsson, O. & Alaupovic, P., 1993. Lipoprotein metabolism and renal failure. *Am. J. Kidney Dis.* 21:573-92.
- Aviram, M., Rosenblat, M., Bisgaier, C.L., Newton, R.S., Primo-Parmo, S.L., La Du, B.N., 1998. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. *J. Clin. Invest.* 101(8): 1581–1590.
- Aviram, M., Rosenblat, M., 2005. Paraoxonases and cardiovascular diseases: pharmacological and nutritional influences. *Curr Opin Lipidol.* 16(4):393–399. doi: 10.1097/01.mol.0000174398.84185.0f.
- Bakaev, V.V., Efremov, A.V., Tityaev, I.I., 1999. Low levels of dehydroascorbic acid in uraemic serum and the partial correction of dehydroascorbic acid deficiency by haemodialysis. *Nephrol. Dial. Transplant.* 14:1472–4.
- Beltowski, J., 2005. Protein homocysteinylation: a new mechanism of atherogenesis ?. *Postepy Hig Med Dosw.* 59:392–404.
- Ben-David, M., Elias, M., Filippi, J.J., Dunach, E., Silman, I., Sussman, J.L., Tawfik, S., 2012. Catalytic versatility and backups in enzyme active sites: the case of serum paraoxonase 1. *J Mol Biol.* 418(3-4):181– 196. doi: 10.1016/j.jmb.2012.02.042.
- Bévier, A., Novel-Catin, E., Blond, E., Pelletier, S., Parant, F., Koppe, L., dan Fouque, D., 2022. Water Soluble Vitamins and Trace Elements Losses during On-Line Hemodiafiltration. *Nutrients.* 14:3454. <https://doi.org/10.3390/nu14173454>.

- Biniaz, V., Sadeghi Shermeh, M., Ebadi, A., Tayeb, A., Einollahi, B., 2014. Effect of Vitamin C supplementation on C reactive protein levels in patients undergoing hemodialysis: A randomized, double blind, placebo-controlled study. *Nephrourol Mon.* 6(1):e13351.
- Blah-Nelson, D., Krüger, D.M., Szeler, K., David, M.B., Kamerlin, S.C.L., 2017. Active site hydrophobicity and the convergent evolution of paraoxonase activity in structurally divergent enzymes: the case of serum paraoxonase 1. *J. Am. Chem. Soc.*, 139(3):1155–1167.
- Boeshoten EW, Schriever J, Krediet RT, Arisz L., 1984. Vitamin deficiencies in CAPD patients. *Perit. Dial. Bull.* 4 (Suppl): S7.
- Bonomini, M., Piscitani, L., Di Liberato, L., Sirolli, V., 2022. Biocompatibility of Surface-Modified Membranes for Chronic Hemodialysis Therapy. *Biomedicines.* 10:844.
- Bowden, R. G., Paul M. La Bounty, Brian D. Shelmadine, A Alexander Beaujean, Ronald L. Wilson and Stuart Hebert. 2011. Reverse Epidemiology of Lipid-Death Associations in a Cohort of End-Stage Renal Disease Patients. *Nephron Clinical Practice* 119: c214 - c219.
- Calla, M., dan Lynch, S., 2006. Vitamin C preserves the cardio-protective paraoxonase activity of high-density lipoprotein during oxidant stress. *Arch Biochem Biophys.* 452(2):129– 137. doi: 10.1016/j.abb.2006.06.012.
- Campo, S., Lacquaniti, A., Trombetta, D., Smeriglio, A., Monardo, P., 2022. Immune System Dysfunction and Inflammation in Hemodialysis Patients: Two Sides of the Same Coin. *J. Clin. Med.* 11:3759.
- Canavese, C., Petrarulo, M., Massarenti, P., Berutti, S., Fenoglio, R., Pualetto, D., Lanfranco, G., Bergamo, D., Sandri, L., Marangella, M., 2005. Long-term, low-dose, intravenous vitamin C leads to plasma calcium oxalate supersaturation in hemodialysis patients. *Am. J. Kidney Dis.* 45:540-549.
- Carr, A.C., Zhu, B.Z., Frei, B., 2000. Potential antiatherogenic mechanisms of ascorbate (vitamin C) and alpha-tocopherol (vitamin E). *Circ Res.* 87:349-354.
- Catabay, C., Obi, Y., Streja, E., Soohoo, M., Park, C., Rhee, C.M., Kovesdy, C.P., Hamano, T., Kalantar-Zadeh, K. 2017. Lymphocyte Cell Ratios and Mortality among Incident Hemodialysis Patients. *Am J Nephrol.* 46(5):408-416. doi: 10.1159/000484177. Epub 2017 Nov 7. PMID: 29130984; PMCID: PMC5777311.
- Chaghouri, P., Maalouf, N., Peters, S.L., Nowak, P.J., Peczak, K., Zasowska-Nowak, A., et al., 2021. Two Faces of Vitamin C in Hemodialysis Patients: Relation to Oxidative Stress and Inflammation. *Nutrients.* 13(3):791.
- Chan, D., Irish, A., Dogra, G., 2005. Efficacy and safety of oral versus intravenous ascorbic acid for anaemia in haemodialysis patients. *Nephrology* 10:336–340.
- Chang, T.I., Streja, E., Soohoo, M., Kim, T.W., Rhee, C.M., Kovesdy, C.P., Kashyap, M.L., Vaziri, N.D., Kalantar-Zadeh, K., Moradi, H. 2017. Association of Serum Triglyceride to HDL Cholesterol Ratio with All-Cause and Cardiovascular Mortality in Incident Hemodialysis Patients. *Clin J Am Soc Nephrol.* 12(4):591-602. doi: 10.2215/CJN.08730816. Epub 2017 Feb 13. PMID: 28193609; PMCID: PMC5383388.

- Chang, T.I., Streja, E., Ko, G.J., Naderi, N., Rhee, C.M., Kovesdy, C.P., Kashyap, M.L., Vaziri, N.D., Kalantar-Zadeh, K., Moradi, H. 2018. Inverse Association Between Serum Non-High-Density Lipoprotein Cholesterol Levels and Mortality in Patients Undergoing Incident Hemodialysis. *J. Am. Heart Assoc.* 7:e009096. doi: 10.1161/JAHA.118.009096.
- Chistiakov, D.A., Melnichenko, A.A., Orekhov, A.N., Bobryshev, Y.V., 2017. Paraoksonase and atherosclerosis-related cardiovascular diseases. *Biochimie.* 132:19–27.
- Cofan, F., Vela, E., Cleries, M., 2006. Analysis of dyslipidemia in patients on chronic hemodialysis in Catalonia. *Atherosclerosis.* 184:94–102).
- Coffery, M.D., Cole, R.A., Colles, S.M., Chisoim, G.M. 1995. In vitro cell injury by oxidized low density lipoprotein involves lipid hydroperoxide-induced formation of alkoxy, lipid, and peroxy radicals. *J Clin Invest.* 96: 1866–73.
- Collins, A.J., Kasiske, B., Herzog, C., Frederick, P., Eggers, P., Agodoa, L., 2005. Excerpts from the United States Renal Data System 2004 annual data report: atlas of end-stage renal disease in the United States. *Am. J. Kidney Dis.* 45 (Suppl 1): A5-7, S1-280.
- Cristol, J.P., Canaud, B., Rabesandratana, H., Gaillard, I., Serre, A., Mion, C. 1994. Enhancement of reactive oxygen species production and cell surface markers expression during hemodialysis. *Nephrol Dial Transplant.* 9:389-94.
- Dantoine, T. F., Debord, J., Charmes, J.P., Merle, L., Marquet, P., Lachantre, G., Leroux-Robert, C., 1998. Decrease of serum paraoksonase activity in chronic renal failure. *J. Am. Soc. Nephrol.* 9(11):2082–2088.
- David, M.W., 1996. Chloramine Removal From Water Used in Hemodialysis. *Advances in Renal Replacement Therapy.* Vol. 3, No. 4 (2):337-347.
- Deakin, S.P., Bioletto, S., Bochaton-Piallat, M.L., James, R.W., 2011. HDL-associated paraoksonase-1 can redistribute to cell membranes and influence sensitivity to oxidative stress. *Free Radic. Biol. Med.* 50:102–109.
- Deicher, R., Ziai, F., Bieglmayer, C., Schillinger, M., Hörl, W.H., 2005. Low total Vitamin C plasma level is a risk factor for cardiovascular morbidity and mortality in hemodialysis patients. *J Am Soc Nephrol.* 16:1811-8.
- Descombes, E., Hanck, A.B., Fellay, G., 1993. Water soluble vitamins in chronic hemodialysis patients and need for supplementation. *Kidney Int.* 43:1319-1328.
- De Vriese, A.S., Borrey, D., Mahieu, E., Claeys, I., Stevens, L., Vanhaeverbeke, A., Roelens, M., Langlois, M.R., 2007. Oral Vitamin C Administration Increases Lipid Peroxidation in Hemodialysis Patients. *Nephron Clin. Pract.* 108:c28–c34.
- Dhariwal, K.R.; Hartzell, W.O.; Levine, M. Ascorbic acid and dehydroascorbic acid measurements in human plasma and serum. *Am. J. Clin. Nutr.* 1991, 54, 712–716.
- Dominiczak, M.H. & Caslake, M.J., 2011. Apolipoproteins: metabolic role and clinical biochemistry applications. *Ann. Clin. Biochem.* 48:498-515.

- Dounousi, E., Bouba, I., Spoto, B., Pappas, K., Tripepi, G., Georgiou, I., *et al.*, 2016. A Genetic biomarker of oxidative stress, the paraoxonase-1 Q192R gene variant, associates with cardiomyopathy in CKD: a longitudinal study. *Oxid Med Cell Longev.* 2016:1507270– 1507277. doi: 10.1155/2016/1507270.
- Duni, A., Liakopoulos, V., Rapsomanikis, K.P., Dounousi, E., 2017. Chronic kidney disease and disproportionately increased cardiovascular damage: does oxidative stress explain the burden? *Oxid Med Cell Longev.* 2017:9036450– 9036415. doi: 10.1155/2017/9036450.
- Eckerson, H., Romson, J., Wyte, C., La Du, B.N., 1983. The human serum paraoxonase/arylesterase polymorphism. *Am J Genet.* 35:1126–1138.
- El Mashad, G.M., ElSayed, H.M., A Nosair, N., 2016. Effect of vitamin C supplementation on lipid profile, serum uric acid, and ascorbic acid in children on hemodialysis. *Saudi J. Kidney Dis. Transpl.* 27:1148–1154.
- Fain, O., 2005. Musculoskeletal manifestations of scurvy. *Joint Bone Spine.* 72:124–128.
- Ferretti, G., Bacchetti, T., Marchionni, C., *et. al.*, 2001. Effect of glycation of high density lipoproteins on their physicochemical properties and on paraoxonase activity. *Acta Diabetol.* 38:163–9.
- Ferretti, G., Bacchetti, T., Marotti, E., Curatola, G., 2003. Effect of homocysteinylation on human high-density lipoproteins: a correlation with paraoxonase activity. *Metabolism.* 52:146–51.
- Ferretti, G., Bacchetti, T., Busni, D., Rabini, R.A., Curatola, G., 2004. Protective effect of paraoxonase activity in high-density lipoproteins against erythrocyte membranes peroxidation: a comparison between healthy subjects and type 1 diabetic patients. *J. Clin. Endocrinol. Metab.* 89:2957–62.
- Ferretti, G., Bacchetti, T., Moroni, C., Savino, S., Liuzzi, A., Balzola, F., Bicchiega, V., 2005. Paraoxonase Activity in High-Density Lipoproteins: A Comparison between Healthy and Obese Females, *The Journal of Clinical Endocrinology & Metabolism*, Volume 90, Issue 3, Pages 1728–1733.
- Ferretti, G., Bacchetti, T., Masciangelo, S., Pallotta, G., 2008. Lipid peroxidation in hemodialysis patients: effect of vitamin C supplementation. *Clin. Biochem.* 41(6): 381-386. doi: 10.1016/j.clinbiochem.2007.12.011.
- Foley, R.N., Parfrey, P.S., Sarnak, M.J., 1998. Epidemiology of cardiovascular disease in chronic renal disease. *J. Am. Soc. Nephrol.* 9 (Suppl.):S16-23.
- Fouque, D., Vennegeer, M., Wee, P.T., Wanner, C., Basci, A., Canaud, B., Haage, P., Konner, K., Kooman, J., MartinMalo, A., Pedrini, L., Pizzarelli, F., Tattersall, J., Tordeur, J., Vanholder, R., 2007. EBPG Guideline on Nutrition. *Nephrol. Dial. Transplant.* 22(Suppl. 2):ii 45- 87.
- Friedewald, W.T., Levy, R.I., Fredrickson, D.S., 1972. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. *Clin Chem.* 18:499–502.
- Galle J, Wanner C., 1997. Oxidative stress and vascular injury relevant for atherogenesis in uremic patients? *Nephrol Dial Transplant.* 12: 2480–3.

- García-Escobar, A., Vera-Vera, S., Tébar-Márquez, D., Rivero-Santana, B., Jurado-Román, A., Jiménez-Valero, S., Galeote, G., Cabrera, J.Á., Moreno, R. 2023. Neutrophil-to-lymphocyte ratio an inflammatory biomarker, and prognostic marker in heart failure, cardiovascular disease and chronic inflammatory diseases: New insights for a potential predictor of anti-cytokine therapy responsiveness. *Microvasc Res.* 150:104598. doi: 10.1016/j.mvr.2023.104598. Epub 2023 Aug 24. PMID: 37633337.
- Gastaldello, K., Vereerstraeten, A., Nzame-Nze, T., Vanherweghem, J.L., Tielemans, C., 1995. Resistance to erythropoietin in iron-overloaded haemodialysis patients can be overcome by ascorbic acid administration. *Nephrol Dial Transplant.* 10 Suppl 6: 44-47 [PMID: 8524494].
- Gbandjaba, N. Y., Ghalim, N., Hassar, M., Berrougui, H., Labrazi, H., Taki, H., *et al.*, 2012. Paraoxonase activity in healthy, diabetic, and hemodialysis patients. *Clin. Biochem.* 45:470–474.
- Gęgotek, A., Skrzydlewska, E. Antioxidant Properties of Ascorbic Acid. Encyclopedia. Available online: <https://encyclopedia.pub/entry/29723> (accessed on 16 March 2025).
- Getz, G.S., Reardon, C.A., 2004. Paraoxonase, a cardioprotective enzyme: continuing issues. *Curr Opin Lipidol.* 15(3):261–267.
- Giancaspro, V., Nuzziello, M., Pallotta, G., Sacchetti, A., Petrarulo, F., 2000. Intravenous ascorbic acid in hemodialysis patients with functional iron deficiency: a clinical trial. *J. Nephrol.* 13:444-449.
- Gilmour ER, Hartley GH, Goodship THJ., 1993. Trace elements and vitamins in renal disease. In: Mitch WE, Klahr S, editors. Nutrition and the kidney. Boston: Little Brown. 114–31.
- Ginsberg, G., Neafsey, P., Hattis, D., Guyton, K.Z., Johns, D.O., Sonawane, B., 2009. Genetic polymorphism in paraoxonase 1 (PON1): Population distribution of PON1 activity. *J. Toxicol. Environ. Health B.* 12:473–507.
- Grzegorzewska, A.E., Adamska, P., Iwańczyk-Skalska, E. *et al.* 2021. Paraoxonase 1 concerning dyslipidaemia, cardiovascular diseases, and mortality in haemodialysis patients. *Sci Rep* 11, 6773. <https://doi.org/10.1038/s41598-021-86231-0>.
- Grundy, S.M., Stone, N.J., Bailey, A.L., Beam, C., Birtcher, K.K., Blumenthal, R.S., Braun, L.T., de Ferranti, S., Faiella-Tommasino, J., Forman, D.E., *et al.*, 2019. 2018 AHA / ACC / AACVPR / AAPA / ABC / ACPM / ADA / AGS / APhA /ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Circulation.* 139: e1082–e1143.
- Gugliucci, A., Mehlhaff, K., Kinugasa, E., Ogata, H., Hermo, R., Schulze, J., Kimura, S. 2007. Paraoxonase-1 concentrations in end-stage renal disease patients increase after hemodialysis: correlation with low molecular weight solute clearance. *Clin Chim Acta.* 377:213–220.

- Gugliucci, A., Kinugasa, E., Kotani, K., et al. 2011. Serum paraoxonase 1 (PON1) lactonase activity is lower in end-stage renal disease patients than in healthy control subjects and increases after hemodialysis. *Clin Chem Lab Med.* 49(1):61–67. doi: 10.1515/CCLM.2011.004.
- Gugliucci, A., Kotani, K., Kimura, S. 2012. Paraoxonase 1 in chronic kidney failure. *J Lipids.* 2012:726048. doi: 10.1155/2012/726048. PMID: 22523692; PMCID: PMC3317201.
- Gonet, B., Domek, H., 2003. Hemodializa pozaustrojowa a status antyoksydacyjny u ludzi, *Czynniki Ryzyka.* 2(4):112–118.
- Gyurászová, M., Gurecká, R., Bábíčková, J., Tóthová, E. 2020. Oxidative Stress in the Pathophysiology of Kidney Disease: Implications for Noninvasive Monitoring and Identification of Biomarkers. *Oxidative Med. Cell. Longev.* 5478708.
- Haagen, L, Brock, A., 1992. A New Automated Method for Phenotyping Arylesterase (EC 3.1.1.2) Based Upon Inhibition of Enzymatic Hydrolysis of 4-Nitrophenol Acetate by Phenyl Acetate. *Eur. J. Clin. Chem. Clin. Biochem.* 30:391-395.
- Halliwell, B., 1999. Vitamin C: Poison, prophylactic or panacea?. *Trends Biochem. Sci.* 24:255–259.
- Handelman, G.J., 2007. Vitamin C deficiency in dialysis patients – Are we perceiving the tip of an iceberg?. *Nephrol. Dial. Transplant.* 22:328-31.
- Hasan, Y.K., Alsultan, M., Anan, M.T., Hassan, Q., Basha, K., 2023. The prevalence of dyslipidemia in patients on hemodialysis: a cross-sectional study from Syria. *Ann. Med. Surg.* 85(8): 3838-3844.
- Hastjarjo, T.D., 2019. Rancangan Eksperimen-Kuasi. *Buletin Psikologi.* 27 (2):187-203.
- Hill, C. and Kelly, E. 2024. 20 Foods That Are High in Vitamin C. Healthline. <https://www.healthline.com/nutrition/vitamin-c-foods#20-foods-high-in-vit-c>.
- Himmelfarb, J., Stenvinkel, P., Alp-Ikizler, T., Hakim, R.M. 2002. The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. *Kidney Int.* 62:1524-38.
- Hodis, H.N., Mack, W.J., LaBaree, L., Cashin-Hemphill, L., Sevanian, A., Johnson, R., Azen, S.P. 1995. Serial coronary angiographic evidence that antioxidant vitamin intake reduces progression of coronary artery atherosclerosis. *JAMA.* 273: 1849–54.
- Holzer, M., Trieb, M., Konya, V., Wadsack, C., Heinemann, A., Marsche, G. 2013. Aging affects high density lipoprotein composition and function. *Biochim. Biophys. Acta.* 1831(9):1442-1448. doi : 10.1016/j.bbalip.2013.06.004.
- Hoy, M.K., Goldman, J.D., Moshfegh, A. 2022. Potassium Intake of the U.S. Population: What We Eat in America, NHANES 2017-2018. FSRG Dietary Data Briefs. Beltsville (MD): United States Department of Agriculture (USDA).
- Humbert, R., Adler, D.A., Disteche, C.M., Hassett, C., Omiecinski, C.J., Furlong, C.E. 1993. The molecular basis of the human serum paraoxonase activity polymorphism. *Nat. Genet.* 3:73–76. doi: 10.1038/ng0193-73.

- Ikeda, Y., Suehiro, T., Itahara, T., Inui, Y., Chikazawa, H., Inoue, M., *et al.*, 2007. Human serum paraoxonase concentration predicts cardiovascular mortality in hemodialysis patients. *Clin. Nephrol.* 67:358–365.
- Indonesian Renal Registry. (2023). 3 th Annual Report of Indonesian Renal Registry 2020. <http://www.indonesianrenalregistry.org>.
- Institute of Medicine (US) Panel on Dietary Antioxidants Related Compounds. 2000. Vitamin C, *Dietary Reference Intakes for Vitamin C, Vitamin E, Selenium, and Carotenoids. The National Academies Press, Washington, DC.* 95–185.
- Issana Marques de Oliveira, Daniela Barbieri Hauschild, Roberta Pieri Machado, Bruna Soares Marques, Elisabeth Wazlawik, 2024. Oral vitamin C supplementation decreased low-density lipoprotein in adults on hemodialysis: A systematic review and meta-analysis. *Nutrition Research.* ISSN 0271-5317, <https://doi.org/10.1016/j.nutres.2024.09.014>).
- Itahara, T., Suehiro, T., Ikeda, Y., Inoue, M., Nakamura, T., Kumon, Y., Kawada, M., dan Hashimoto, K., 2000. Serum Paraoxonase and Arylesterase Activities in Hemodialysis Patients. *J. Atheroscler. Thromb.* 7:152-158.
- Iqbal, M.P., Khan, A., H., Mehboobali, N., Iqbal, S., P. 2007. Human paraoxonase and hdl-cholesterol in pakistani patients with acute myocardial infarction and normal healthy adults. *Pak J Med Sci.* Vol. 23 No. 5 659-664.
- Jackson, P., Loughrey, C.M., Lightbody, J.H., McNamee, P.T., Young, I.S. 1995. Effect of hemodialysis on total antioxidant capacity and serum antioxidants in patients with chronic renal failure. *Clin. Chem.* 41:1135–1138.
- Jahnke, M.G., Rock, C.L., Carter, C.M., Kelly, M.P., Gorenzo, D.W., Messana, J.M., Swartz, R.D., Rehan, A., Jones, M.F., dan Lipschutz, D., 1996. Antioxidant Vitamins and Carotenoids in Hemodialysis and Peritoneal Dialysis Patients. *Journal of Renal Nutrition.* 6(2):79-88.
- Jakubowski, H., 1999. Protein homocysteinylation: possible mechanism underlying pathological consequences of elevated homocysteine levels. *FASEB J.* 13:2277–2283.
- Jakubowski, H., 2000. Calcium-dependent human serum homocysteine thiolactone hydrolase. A protective mechanism against protein N-homocysteinylation. *J. Biol. Chem.* 275:3957–3962.
- James, R. dan Deakin, S.. 2004. The importance of high-density lipoproteins for paraoxonase-1 secretion, stability, and activity. *Free Radic Biol Med.* 37(12):1986–1994. doi: 10.1016/j.freeradbiomed.2004.08.012.
- Jaouad, L., De-Guise, C., Berrougui, H., Cloutier, M., Isabelle, M., Fulop, T., *et al.*, 2006. Age-related decrease in high-density lipoproteins antioxidant activity is due to an alteration in the PON1's free sulfhydryl groups. *Atherosclerosis.* 185:191–200.
- Jialal, L., Grundy, S.M., 1993. Effect of combined supplementation with alpha-tocopherol, ascorbate, and beta carotene on low-density lipoprotein oxidation. *Circulation.* 88:2780-2786.

- Jin, D.C., Yun, S.R., Lee, S.W., Han, S.W., Kim, W., Park, J., Kim, Y.K., 2015. Lessons from 30 years' data of Korean end-stage renal disease registry, 1985-2015. *Kidney Res. Clin. Pract.* 34(3):132-9.
- Joan C. Lo, Alan S. Go, Malini Chandra, Dongjie Fan, George A. Kaysen, GFR. 2007. Body Mass Index, and Low High-Density Lipoprotein Concentration in Adults With and Without CKD. *American Journal of Kidney Diseases*, Volume 50, Issue 4, Pages 552-558, ISSN 0272-6386, <https://doi.org/10.1053/j.ajkd.2007.07.011>.
- Johnson-Davis, K.L., Fernelius, C., Eliason, N.B., Wilson, A., Beddhu, S., Roberts, W.L., 2011. Blood enzymes and oxidative stress in chronic kidney disease: a cross sectional study. *Ann Clin Lab Sci.* 41(4):331-339.
- Johnston, C.S., Steinberg, F.M., Rucker, R.B., 2007. Ascorbic acid. In: Zempleni, J., Rucker, R.B., McCormick, D.B., Suttie, J.W. (Ed): *Handbook of vitamins.* 4: 489-520. CRC, Boca Raton.
- Jukema, J.W., Liem, A.H., Dunselman, P.H., van der Sloot, J.A., Lok, D.J., Zwinderman, A.H. 2005. LDL-C/HDL-C ratio in subjects with cardiovascular disease and a low HDL-C: results of the RADAR (Rosuvastatin and Atorvastatin in different Dosages And Reverse cholesterol transport) study. *Curr Med Res Opin.* 21(11):1865-74. doi: 10.1185/030079905X74952. PMID: 16307708.
- Juretic, D., Tadijanovic, M., Rekić, B., Simeon-Rudolf, V., Reiner, E., Baricic, M., 2001. Serum paraoxonase activities in hemodialyzed uremic patients: cohort study. *Croat. Med. J.* 42:146-50.
- Kahvecioglu, S., Ersoy, A., Gullulu, M., Dirican, M. 2014. Effects of calcineurin inhibitors on paraoxonase and arylesterase activity after a kidney transplant. *Exp Clin Transplant.* 12(4):334-342. doi: 10.6002/ect.2013.0110.
- Kalantar-Zadeh, K., Kopple, J.D. 2003. Trace elements and vitamins in maintenance dialysis patients. *Adv Ren Replace Ther.* 10(3):170-182).
- Kalantar-Zadeh, K., Abbott, K.C., Salahudeen, A.K., Kilpatrick, R.D., Horwich, T.B. 2005. Survival advantages of obesity in dialysis patients. *Am J Clin Nutr.* 81(3):543-54. doi: 10.1093/ajcn/81.3.543. PMID: 15755821.
- Kalantar-Zadeh, K., Braglia, A., Chow, J., Kwon, O., Kuwae, N., Colman, S., Cockram, D.B., Kopple, J.D., 2005. An anti-inflammatory and antioxidant nutritional supplement for hypoalbuminemic hemodialysis patients: a pilot/feasibility study. *J Ren Nutr.* 15:318-331.
- Kaseda, R., Tsuchida, Y., Gamboa, J.L., Zhong, J., Zhang, L., Yang, H., et al. 2018. Angiotensin receptor blocker vs ACE inhibitor effects on HDL functionality in patients on maintenance hemodialysis. *Nutr Metab Cardiovasc Dis.* 28(6):582-591. doi: 10.1016/j.numecd.2018.02.020. Epub 2018 Mar 8. PMID: 29691148; PMCID: PMC5959764.
- Kim, T., Streja, E., Soohoo, M., Rhee, C.M., Eriguchi, R., Kim, T.W., Chang, T.I., Obi, Y., Kovesdy, C.P., Kalantar-Zadeh, K. 2017. Serum Ferritin Variations and Mortality in Incident Hemodialysis Patients. *Am J Nephrol.* 46(2):120-130. doi: 10.1159/000478735. Epub 2017 Jul 14. PMID: 28704813; PMCID: PMC5926176.

- Komiyama, M., Ozaki, Y., Miyazaki, Y., Katanasaka, Y., Sunagawa, Y., Funamoto, M., Shimizu, K., Yamakage, H., Sato-Asahara, N., Yasoda, A., Wada, H., Morimoto, T., Hasegawa, K. 2021. Neutrophil/lymphocyte ratio is correlated with levels of inflammatory markers and is significantly reduced by smoking cessation. *J Int Med Res.* 49(6):3000605211019223. doi: 10.1177/03000605211019223. PMID: 34187206; PMCID: PMC8258763.
- Kaysen, G.A., Eiserich, J.P., 2004. The role of oxidative stress-altered lipoprotein structure and function and microinflammation on cardiovascular risk in patients with minor renal dysfunction. *J. Am. Soc. Nephrol.* 15:538–48.
- Kazmierczak-Baran'ska, J., Boguszewska, K., Adamus-Grabicka, A., Karwowski, B.T., 2020. Two Faces of Vitamin C—Antioxidative and Pro-Oxidative Agent. *Nutrients.* 12:1501.
- KDIGO. 2013. Kidney Disease: Improving Global Outcomes Lipid Guideline Development Work Group Members KDIGO clinical practice guideline for lipid management in chronic kidney disease. *Kidney Int Suppl.* 3:263–305. doi: 10.1038/kisup.2013.42.
- K/DOQI Workgroup, 2005. K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients. *Am. J. Kidney Dis.* 45:1-153.
- Kemenkes RI, 2018. Laporan Nasional Riskesdas 2018. Jakarta: Kementerian Kesehatan RI, Badan Penelitian dan Pengembangan Kesehatan. *Kementerian Kesehatan RI.* 53(9):1689-1699.
- Kennedy, S.S., Perilloux, A., Pereira, R.C., Handelman, G., Wesseling-Perry, K., Salusky, I.B., 2021. Vitamin C overload may contribute to systemic oxalosis in children receiving dialysis. *Pediatr. Nephrol.* 36:435–441.
- Keven, K., Kutlay, S., Nergizoglu, G., Ertürk, S., 2003. Randomized, crossover study of the effect of vitamin C on EPO response in hemodialysis patients. *Am. J. Kidney Dis.* 41:1233-1239.
- Khajehdehi, P., 2000. Effect of vitamins on the lipid profile of patients on regular hemodialysis. *Scand. J. Urol. Nephrol.* 34:62-66.
- Khajehdehi, P., Mojerlou, M., Behzadi, S., Rais-Jalali, G.A., 2001. A randomized, double-blind, placebo-controlled trial of supplementary vitamins E, C and their combination for treatment of haemodialysis cramps. *Nephrol. Dial. Transplant.* 16:1448– 1451.
- Kim, D.S., Burt, A.A., Ranchalis, J.E., Richter, R.J., Marshall, J.K., Nakayama, K.S., Jarvik, E.R., Eintracht, J.F., Rosenthal, E.A., Furlong, C.E., Jarvik, G.P. 2012. Dietary cholesterol increases paraoxonase 1 enzyme activity. *J Lipid Res.* 53(11):2450-8. doi: 10.1194/jlr.P030601. Epub. PMID: 22896672; PMCID: PMC3466014.
- Kosmas, C.E., Rodriguez Polanco, S., Bousvarou, M.D., Papakonstantinou, E.J., Peña Genao, E., Guzman, E., Kostara, C.E. 2023. The Triglyceride/High-Density Lipoprotein Cholesterol (TG/HDL-C) Ratio as a Risk Marker for Metabolic Syndrome and Cardiovascular Disease. *Diagnostics (Basel).* 1;13(5):929. doi: 10.3390/diagnostics13050929. PMID: 36900073; PMCID: PMC10001260.

- Kotur-Stevuljevic, J., Simic-Ogrizovic, S., Dopsaj, V., Stefanovic, A., Vujovic, A., Ivanic-Corlomanovic, T., Spasic, S., Kalimanovska-Spasojevic, V., Jelic-Ivanovic, Z., 2012. A hazardous link between malnutrition, inflammation and oxidative stress in renal patients. *Clin Biochem.* 45(15):1202–1205. doi: 10.1016/j.clinbiochem.2012.04.021.
- Kotur-Stevuljević, J., Peco-Antic, A., Spasic, S., Stefanovic, A., Paripovic, D., Kostic, M., et al., 2013. Hyperlipidemia, oxidative stress, and intima media thickness in children with chronic kidney disease. *Pediatr. Nephrol.* 28:295–303.
- Kritchevsky, S.B., Shimakawa, T., Tell, G.S., Dennis, R., Carpenter, M., Fckfeldt, J.H., et al., 1995. Dietary antioxidant and carotid wall thickness. The ARIC Study. *Circulation.* 92: 2142–50.
- Kuchta, A., Pacanis, A., Kortas-Stempak, B., Cwiklińska, A., Ziętkiewicz, M., Renke, M., Rutkowski, B., 2011. Estimation of oxidative stress markers in chronic kidney disease. *Kidney Blood Press Res.* 34(1):12–19. doi: 10.1159/000321508.
- Kumar, S., Batra, J., Prasad-Sah, S., Kumar, D., Iqbal, S., Arora, M., Sharma, S. 2022. Paraoksonase 1 Activities and Lipid Parameters in Hypertension and Their Association with Chronic Alcoholism. *International Journal of Integrated Health Sciences.* Vol. 10(1):7–11. <https://doi.org/10.15850/ijhs.v10n1.2595>.
- Kuo, C.L., La Du, B.N. 1998. Calcium binding by human and rabbit serum paraoxonases. Structural stability and enzymatic activity. *Drug Metab. Dispos. Biol. Fate Chem.* 26:653–660.
- Kyte, D., Bishop, J., Brettell, E., Calvert, M., Cockwell, P., Dutton, M., Eddington, H., Hadley, G., Ives, N.J., Jackson, L.J., Stringer, S., Valente, M., 2018. Use of an electronic patient-reported outcome measure in the management of patients with advanced chronic kidney disease: the RePROM pilot trial protocol. *BMJ Open.* 8(10):e026080.
- Lemeshow, S., Lwanga, S.K. 1991. Sample size determination in health studies' a practical manual. World Health Organization, Geneva. ISBN 92 4 154405 8 (NLM Classification WA 950).
- Levey, A.S., Beto, J.A., Coronado, B.E., Eknayan, G., Foley, R.N., Kasiske, B.L., et al., 1998. Controlling the epidemic of cardiovascular disease in chronic renal disease: what do we know? What do we need to learn? Where do we go from here? National Kidney Foundation Task Force on Cardiovascular Disease. *Am. J. Kidney Dis.* 32:853-906.
- Levine, M., Conry-Cantilena, C., Wang, Y., Welch, R.W., Washko, P.W., Dhariwal, K.R., et al., 1996. Vitamin C pharmacokinetics in healthy volunteers: evidence for a recommended dietary allowance. *Proc. Natl. Acad. Sci.* 93:3704–3709.
- Levine, M., Rumsey, S.C., Daruwala, R., Park, J.B., Wang, Y., 1999. Criteria and recommendations for vitamin C intake. *JAMA.* 281:1415–1423.
- Levine, M., Wang, Y., Padayatty, S.J., Morrow, J. 2001. A new recommended dietary allowance of vitamin C for healthy young women. *Proc. Natl. Acad. Sci.* 98:9842–9846.

- Levine, M., Padayatty, S.J., Espey, M.G. 2011. Vitamin C: A concentration-function approach yields pharmacology and therapeutic discoveries. *Adv. Nutr.* 2:78–88.
- Levine, M., Padayatty, S.J., 2014, Vitamin C. In: *Modern Nutrition in Health and disease*, Ross AC, Cabalero B, Cousins RJ, Tucker KL., Ziegler TR. (Ed.), *Lippincott Williams and Wilkins*. 11:416-426. Baltimore, MD.
- Lind L, Lithel H, Wengle B, Werge U, Ljunghall S., 1988. A pilot study of metabolic effects of intravenously given alpha-calcidol in patients with chronic renal failure. *Scand J Urol Nephrol.* 22: 219–22.
- Linus Pauling Institute, 2018. Vitamin C, *Micronutrient Information Center, Oregon State University, Corvallis, OR.* (diunduh 19 Juni 2024).
- Liu, Y., Weisberg, L.S., Langman, C.B., Logan, A., Hunter, K., Prasad, D., *et al.*, 2016. Plasma oxalate levels in prevalent hemodialysis patients and potential implications for ascorbic acid supplementation. *Clin.Biochem.* 49:1133–1139.
- Locsey, L., Seres, I., Sztanek, F., Harangi, M., Padra, J., Kovacs, D., *et al.*, 2013. Relationship between serum paraoxonase and homocysteine thiolactonase activity, adipokines, and asymmetric dimethyl arginine concentrations in renal transplant patients. *Transplant. Proc.* 45:3685–3687.
- Loughrey, C.M., Young, I.S., Lightbody, J.H., McMaster, D., McNamee, P.T., Trimble, E.R. 1994. Oxidative stress in hemo- dialysis. *Q J Med.* 87: 679–83.
- Lunec, J., Holloway, K.A., Cooke, M.S., Faux, S., Griffiths, H.R., Evans, M.D., 2002. Urinary 8-oxo-2'-deoxyguanosine: Redox regulation of DNA repair in vivo?. *Free Radic. Biol. Med.* 33:875–885.
- Maclin, L.J. 1995. Critical assessment of the epidemiological data concerning the impact of the antioxidant nutrients on cancer and cardiovascular disease. *Crit Rev Food Sci Nutr.* 35: 41–50.
- Mackness, M.I., Arrol, S., Durrington, P.N., 1991. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. *FEBS Lett.* 286 : 152–154.
- Mackness, B., Quarek, R., Verreth, W., Mackness, M., Holvoet, P., 2006. Human paraoxonase-1 overexpression inhibits atherosclerosis in a mouse model of metabolic syndrome. *Arterioscler. Thromb. Vasc. Biol.* 26:1545–50.
- Mackness, M., dan Mackness B., 2015. Human paraoxonase-1 (PON1): gene structure and expression, promiscuous activities and multiple physiological roles. *Gene.* 567(1):12–21. doi: 10.1016/j.gene.2015.04.088.
- McRae, M.P. 2008. Vitamin C supplementation lowers serum low-density lipoprotein cholesterol and triglycerides: a meta-analysis of 13 randomized controlled trials. *J Chiropr Med.* 7(2):48-58. doi: 10.1016/j.jcme.2008.01.002. PMID: 19674720; PMCID: PMC2682928
- Maggie, E, Bellazzi R, Falaschi F, Frattoni A, Perani G, Finardi G, *et al.*, 1994. Enhanced LDL oxidation in uremic patients: an additional mechanism for accelerated atherosclerosis? *Kidney Int.* 45: 876–83.

- Mahrooz, A., Zargari, M., Sedighi, O., Shaygani, H., Gohari, G., 2012. Increased oxidized-LDL levels and arylesterase activity/HDL ratio in ESRD patients treated with hemodialysis. *Clin Invest Med.* 35 (3): E144-E151.
- Mancini, M, Parfitt VJ, Rubba P., 1995. Antioxidant in the Mediterranean diet. *Can J Cardiol.* 11 (Suppl G): 105G–9G.
- Marsillach, J, Martínez-Vea A, Marcas L, Mackness, B., Mackness, M., Ferré, N., Joven, J., Camps, J., 2007. Administration of exogenous erythropoietin beta affects lipid peroxidation and serum paraoxonase-1 activity and concentration in predialysis patients with chronic renal disease and anaemia. *Clin Exp Pharmacol Physiol.* 34(4):347–349. doi: 10.1111/j.1440-1681.2007.04552.
- Márquez, A.B., Nazir, S., van der Vorst, E.P.C., 2020. High-Density Lipoprotein Modifications: A Pathological Consequence or Cause of Disease Progression? *Biomedicines.* 8:549. doi: 10.3390/biomedicines8120549.
- Matsumoto, A.K., Maes M., Michelin A.P., Bonifácio K.L., de Oliveira Semeão L., Dal Ben Martins R.F., de Lima Pedrão J.V., Moreira E.G., Delfino V.D.A., Barbosa D.S., 2020. Treatment With Folic Acid Increases Paraoxonase 1 Activity Thereby Improving Chronic Kidney Disease. *Preprints.* doi:10.20944/preprints202003.0472.v1.
- Matsushita, K., Ballew, S.H., Wang, A.Y.M., Kalyesubula, R., Schaeffner, E., Agarwal R., 2022. Epidemiology and Risk of Cardiovascular Disease in Populations with Chronic Kidney Disease. *Nat. Rev. Nephrol.* 18:696–707. doi: 10.1038/s41581-022-00616-6.
- MayoClinic Staff., 2022. Triglycerides: Why do they matter? Triglycerides are an important measure of heart health. Here's why triglycerides matter — and what to do if your triglycerides are too high. [https://www.mayoclinic.org/diseases-conditions/high-bloodcholesterol/indepth/triglycerides/art20048186#:~:text=High%20triglycerides%20may%20contribute%20to,of%20the%20pancreas%20\(pancreatitis\).](https://www.mayoclinic.org/diseases-conditions/high-bloodcholesterol/indepth/triglycerides/art20048186#:~:text=High%20triglycerides%20may%20contribute%20to,of%20the%20pancreas%20(pancreatitis).)
- Miguita, R., Matsumoto, A.K., Michelin, A.P., Morelli, N.R., Baltus, T.H.L., Delfino, V.D.A., Barbosa, D.S. Effect of Dialyzer Reuse on the Activity of Paraoksonase 1 in Patients on Hemodialysis. 2022. *Indian J Nephrol.* 32(6):606-610. doi: 10.4103/ijn.IJN_77_21. Epub 2022 Nov 21. PMID: 36704581; PMCID: PMC9872931.
- Mikolasevic, I.; Žutelija, M.; Mavrinac, V.; Orlic, L. 2017. Dyslipidemia in patients with chronic kidney disease: Etiology and management. *Int. J. Nephrol. Renov. Dis.* 10:35–45.
- Miljkovic, M., Stefanovic, A., Vekic, J., Zeljkovic, A., Gojkovic, T., Simic-Ogrizovic, S., et al., 2018. Activity of paraoxonase 1 (PON1) on HDL2 and HDL3 subclasses in renal disease. *Clin. Biochem.* 60:52–58.
- Mitwalli, A.H., Awatif, A., Al Wakeel, J.S., Isnani, A.C., 2011. Dyslipidemia in Dialysis Patients. *Saudi J Kidney Dis Transpl.* 22(4):689-694.
- Montazerifar, F., Hashemi, M., Karajibani, M., Dikshit M. 2010. Effect of antioxidant vitamins on lipid profile and total antioxidant capacity in hemodialysis patients. *Rawal Medical Journal.* 35(2):120-123.

- Moradi H, Ganji S, Kamanna V., 2010. Increased monocyte adhesion-promoting capacity of plasma in end-stage renal disease – response to antioxidant therapy. *Clin Nephrol.* 74(4):273–281. doi: 10.5414/cnp74273.
- Moradi, H., Streja, E., Kashyap, M.L., Vaziri, N.D., Fonarow, G.C., Kalantar-Zadeh, K. 2014. Elevated high-density lipoprotein cholesterol and cardiovascular mortality in maintenance hemodialysis patients. *Nephrol. Dial. Transplant.* 29:1554–1562. doi: 10.1093/ndt/gfu0220.
- Morena, M., Delbosc, S., Dupuy, A.M., Canaud, B., Cristol, J.P., 2005. Overproduction of reactive oxygen species in end-stage renal disease patients: A potential component of hemodialysis-associated inflammation. *Hemodial. Int.* 9:37–46.
- Morena, M., Martin-Mateo, M., Cristol, J.P., Canaud, B., 2001. Rationale for antioxidant supplementation in hemodialysis patients. *Saudi J. Kidney Dis. Transplant.* 12:312–324.
- National Institute for Health and Care Excellence (NICE). 2023. Cardiovascular disease: risk assessment and reduction, including lipid modification (NG238). *NICE Guidelines.* <https://www.nice.org.uk/guidance/ng238>.
- National Kidney Foundation. 2001. K/DOQI Clinical Practice Guidelines For Hemodialysis Adequacy: Update 2000. *Clinical Practice Guidelines.* 37(1): S7-S64, [https://doi.org/10.1016/S0272-6386\(01\)70005-4](https://doi.org/10.1016/S0272-6386(01)70005-4).
- National Kidney Foundation. 2003. K/DOQI Clinical Practice Guidelines for Managing Dyslipidemias in Chronic Kidney Disease. *Am. J. Kidney Dis.* 41(4,Suppl 3):S39-58.
- Neuen, B. L., Leather, N., Greenwood, A. M., Gunnarsson, R., Cho, Y., & Mantha, M. L., 2015. Neutrophil–lymphocyte ratio predicts cardiovascular and all-cause mortality in hemodialysis patients. *Renal Failure*, 38(1), 70–76. <https://doi.org/10.3109/0886022X.2015.1104990>.
- Nezami, N, Ghorbanihaghjo, A, Argani, H., 2011. Lovastatin enhances paraoxonase enzyme activity and quells low-density lipoprotein susceptibility to oxidation in type 2 diabetic nephropathy. *Clin Biochem.* 44(2-3):165– 170. doi: 10.1016/j.clinbiochem.2010.10.006.
- Nguyen-Khoa, T., Massy, Z.A., De Bandt, J.P., Kebede, M., Salama, L., Lambrey, G., *et al.*, 2001. Oxidative stress and haemodialysis: role of inflammation and duration of dialysis treatment. *Nephrol Dial Transplant.* 16:335–40.
- Nishikimi, M, Yagi, K. 1991. Molecular basis for the deficiency in humans of gulonolactone oxidase, a key enzyme for ascorbic acid biosynthesis. *Am J Clin Nutr.* 54: 1203S-1208S [PMID: 1962571].
- Nishizawa, Y., Shoji, T., Kakiya, R., Tsujimoto, Y., Tabata, T., Ishimura, E., *et al.* 2003. Non-high-density lipoprotein cholesterol (non-HDL-C) as a predictor of

cardiovascular mortality in patients with end-stage renal disease. *Kidney Int Suppl.* 63:2345-6.

Noels, H., Lehrke, M., Vanholder, R., Jankowski, J., 2021. Lipoproteins and Fatty Acids in Chronic Kidney Disease: Molecular and Metabolic Alterations. *Nat. Rev. Nephrol.* 17:528–542. doi: 10.1038/s41581-021-00423-5.

Nordestgaard, B.G., Langsted, A., Mora, S., Kolovou, G., Baum, H., Bruckert, E., Watts, G.F., et al. 2016. European Atherosclerosis Society (EAS) and the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) joint consensus initiative. Fasting is not routinely required for determination of a lipid profile: clinical and laboratory implications including flagging at desirable concentration cut-points—a joint consensus statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine. *Eur Heart J.* 37(25):1944-58. doi: 10.1093/eurheartj/ehw152. Epub 2016 Apr 26. PMID: 27122601; PMCID: PMC4929379.

Notoatmodjo, S., 2018. *Metodologi Penelitian Kesehatan*. Rineka Cipta. Jakarta.

Nursalam, 2013. *Metodologi Penelitian Ilmu Keperawatan: Pendekatan Praktis*. Salemba Medika, Jakarta.

Okubo, K., Ikewaki, K., Sakai, S., et al. 2004. Abnormal HDL apolipoprotein A-I and A-II kinetics in hemodialysis patients: a stable isotope study. *J Am Soc Nephrol.* 15:1008-15.

Okuturlar, Y., Gedikbasi, A., Akalin, N., gnld, M., Yilmaz, D., Mert, M., Harmankaya, O., Soyulu, A., Karakaya, P., Kumbasar, A. 2016. Serum paraoxonase 1 activity in patients with iron deficiency anemia. *Archives of Medical Science : AMS.* 12. 697-703. 10.5114/aoms.2015.48730.

Ota, K., Suehiro, T., Aarii, K., Ikeda, Y., Kumon, Y., Osaki, F., Hashimoto, K., et al., 2005. Effect of pitavastatin on transactivation of human serum paraoxonase 1 gene. *Metabolism.* 54(2):142–150. doi: 10.1016/j.metabol.2004.06.018.

Padayatty, S.J., Katz, A., Wang, Y., Eck, P., Kwon, O., Lee, J.H., Chen, S., et al., 2003. Vitamin C as an Antioxidant: Evaluation of Its Role in Disease Prevention. *J. Am. Coll. Nutr.* 22:18–35.

Padayatty, S.J., Sun, H., Wang, Y., Riordan, H.D., Hewitt, S.M., Katz, A., Wesley, R.A., Levine, M. 2004. Vitamin C pharmacokinetics: Implications for oral and intravenous use. *Ann. Intern. Med.* 140:533–537.

Paul, J.L., Sall, N.D., Soni, T., Poignet, J.L., Lindenbaum, A., Man, N.K., Moatti, N., et al., 1993. Lipid peroxidation abnormalities in hemodialyzed patients. *Nephron.* 64:106–9.

Pawlak, K., Pawlak, D., Mysliwiec, M., 2007. Impaired renal function and duration of dialysis therapy are associated with oxidative stress and proatherogenic cytokine levels in patients with end-stage renal disease. *Clin. Biochem.* 40:81–5.

- Perhimpunan Nefrologi Indonesia (Pernefri). 2003. Pedoman Pelaksanaan Dialisis. *Konsensus Dialisis Pernefri 2003* : 25-52.
- Peuchant, E., Carbonneau, M.A., Dubourg, L., Thomas, M.J., Perromat, A., Vallot, C., Clerc, M. 1994. Lipoperoxidation in plasma and red blood cells of patients undergoing haemodialysis: vitamin A, E, and iron status. *Free Radic Biol Med.* 16: 339–46.
- Précourt, L.P., Amre, D., Denis, A.M., Lavole, J.C., Delvin, E., Seidman, E., *et al.*, 2011. The three-gene paraoxonase family: physiologic roles, actions and regulation. *Atherosclerosis.* 214(1):20–36. doi: 10.1016/j.atherosclerosis.2010.08.076.
- Sarkar, P.D., Shivaprakash, T.M., Madhusudhan, B. 2006. Association between paraoxonase activity and lipid levels in patients with premature coronary artery disease. *Clinica Chimica Acta.*373:77–81, doi:10.1016/j.cca.2006.05.005.
- Rahimi-Ardabili, B, Argani, H, Ghorbanihaghjo, A, Rashtchizadeh, N., Naghavi-Behzad, M., Ghorashi, S., Nezami, N., *et al.*, 2012. Paraoxonase enzyme activity is enhanced by zinc supplementation in hemodialysis patients. *Ren Fail.* 34(9): 1123–1128. doi: 10.3109/0886022X.2012.717479.
- Rahmati, M.A., Craig, R.G., Homel, P., Kaysen, G.A., Levin, N.W., 2002. Serum markers of periodontal disease status and inflammation in hemodialysis patients. *Am. J. Kidney Dis.* 40:983–989.
- Ramos, R., Gómez-Geriqué, N., Martínez-Castelao, A. 2005. Estrés oxidativo de las lipoproteínas y efecto antioxidante de la vitamina C un año después de iniciar hemodiálisis [Lipoprotein oxidation profile in end stage renal disease patients. Role of vitamin C supplementation]. *Nefrologia.* 25(2):178-84. Spanish. PMID: 15912655.
- Rajković, M. G., Barišić, K., Juretić, D., Grubišić, T.Z., Flegar-Meštrić, Z., Rumora, L., 2011. Polymorphisms of pon1 and pon2 genes in hemodialyzed patients. *Clin. Biochem.* 44:964–968.
- Rezapour, M., Payani, E., Taran, M., Ghatari, A.R., Khavanin-Zadeh, M. 2017. Roles of triglyceride and phosphate in atherosclerosis of diabetic hemodialysis patients. *Med J Islam Repub Iran.* 15;31:80. doi: 10.14196/mjiri.3180. PMID: 29445708; PMCID: PMC5804422.
- Ribeiro, S., do Sameiro Faria, M., Mascarenhas-Melo, F., Freitas, I., Nascimento, H., Mendonça, M.I., *et al.*, 2012. Main determinants of PON1 activity in hemodialysis patients. *Am J Nephrol.* 36(4):317–323. doi: 10.1159/000342235.
- Rosenstein, K., Tannock, L.R. 2022. Dyslipidemia in Chronic Kidney Disease. In: Feingold KR, Anawalt B, Blackman MR, *et al.*, editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000-. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK305899/>.
- Ross, M.A., 1994. Determination of ascorbic acid and uric acid in plasma by high-performance liquid chromatography. *J Chromatogr. B. Biomed. Appl.* 657:197-200.
- Rosta, V., Trentini, A., Passaro, A., Zuliani, G., Sanz, J.M., Bosi, C., Bonaccorsi, G., Bellini, T., Cervellati, C. 2020. Sex Difference Impacts on the Relationship

- between Paraoxonase-1 (PON1) and Type 2 Diabetes. *Antioxidants (Basel)*. 9(8):683. doi: 10.3390/antiox9080683. PMID: 32751395; PMCID: PMC7463677.
- Rowe, S., Carr, A.C., 2020. Global Vitamin C Status and Prevalence of Deficiency: A Cause for Concern? *Nutrients*. 12(7).
- Saini, M., Vamne, A., Kumar, V., Chandel, M.S. 2021. Lipid Profile in Pre-dialysis and Post-dialysis End Stage Renal Disease Patients: A Cross-Sectional Comparative Study in Lucknow, India. *Cureus*. Vol.13(9):e18240. doi: 10.7759/cureus.18240. PMID: 34712525; PMCID: PMC8542343.
- Samouilidou, E.C., Karpouza, A.P., Kostopoulos, V., Bakirtzi, T., Pantelias, K., Petras, D., Tzanatou-Exarchou, H., *et al.*, 2012. Lipid abnormalities and oxidized LDL in chronic kidney disease patients on hemodialysis and peritoneal dialysis. *Ren Fail*. 34(2):160–164. doi: 10.3109/0886022X.2011.641515.
- Samouilidou, E., Kostopoulos, V., Liaouri, A., Kioussi, E., Vassiliou, K., Bountou, E., *et al.*, 2016. Association of lipid profile with serum PON1 concentration in patients with chronic kidney disease. *Ren. Fail.* 38:1601–1606. <https://doi.org/10.3109/0886022X.2016.1144031>.
- Samouilidou, E.C., Liaouria, A., Kostopoulou, V., Nikasa, D. and Grapsab, E., 2024. Importance of paraoxonase 1 activity in chronic kidney disease. *Renal Failure*. VOL. 46, NO. 2, 2376930.
- Sarandol, E., Erdinc, S., Senol, E., Ersoy, A., Surmen-Gur, E., 2023. Effects of vitamin C supplementation on oxidative stress and serum paraoxonase/arylesterase activities in patients on long-term hemodialysis. *Nefrologia*. Volume 43, Issue 3, 2023, Pages 351-359, ISSN 0211-6995. 11(024):S2013-2514(22)00150-X. doi:10.1016/j.nefro.2021.11.003.
- Sarnak, M.J., Levey, A.S., Schoolwerth, A.C., Coresh, J., Culeton, B., Hamm, L.L., *et al.*, 2003. American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention: Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. *Hypertension*. 42:1050-65.
- Saruhan, E., Olgun, A., Ozturk, K., Erbil, M.K., Akman, S., 2007. Age-Related Paraoxonase Activity Changes in Turkish Population. *Annals of the New York Academy of Sciences*. 1100(1):218-22. doi:10.1196/annals.1395.022.
- Sato, M., Matsumoto, Y., Morita, H., Takemura, H., Shimoi, K., Amano, I., 2003. Effects of vitamin supplementation on microcirculatory disturbance in hemodialysis patients without peripheral arterial disease. *Clin. Nephrol.* 60:28-34.
- Schiavon, R., De Fanti, E., Giavarina, D., Biasioli, S., Cavalcanti, G., dan Guidi, G., 1996. Serum paraoxonase activity is decreased in uremic patients. *Clin. Chim. Acta*. 247:71- 80.
- Scientific Opinion on Dietary Reference, 2013. Values for vitamin C "*EFSA Journal*. 11 (11). doi:10.2903/j.efsa.2013.3418.

- Scott, I.A., Scuffham, P., Gupta, D., Harch, T.M., Borch, J., Richards, B., 2020. Going digital: a narrative overview of the effects, quality and utility of mobile apps in chronic disease self-management. *Aust. Health Rev.* 44(1):62-82.
- Shokri, Y., Variji, A., Nosrati, M., Bahar, A., Bagheri, A., Mahrooj, A., et.al., 2020. Importance of paraoxonase 1 (PON 1) as an antioxidant and antiatherogenic enzyme in the cardiovascular complications of type 2 diabetes: genotypic and phenotypic evaluation. *Diabetes Res Clin Pract.* 161:108067.
- Shroff, G.R, Li, S., Herzog, C.A. 2015. Trends in Mortality Following Acute Myocardial Infarction Among Dialysis Patients in the United States Over 15 Years. *Journal of the American Heart Association.* 4: e002460.
- Siamopoulos, K.C., Elisaf, M. 1997. Is CAPD atherogenic?. *Perit. Dial. Int.* 17(3):227-31.
- Soran, H., Younis, N.N., Charlton-Menys, V., Durrington, P., 2009. Variation in Paraoxonase-1 Activity and Atherosclerosis. *Curr. Opin. Lipidol.* 20:265-274. doi: 10.1097/MOL.0b013e32832ec141.
- Stack, A.G. dan Bloembergen, W.E., 2001. Prevalence and clinical correlates of coronary artery disease among new dialysis patients in the United States: a cross-sectional study. *J. Am. Soc. Nephrol.* 12:1516-23.
- Suehiro, T. et. al., 2002. Serum paraoxonase (PON1) concentration in patients undergoing hemodialysis. *J. Atheroscler. Tromb.* 9:133-138.
- Suematsu, Y., Goto, M., Park, C., Nunes, A.C.F., Jing, W., Streja, E., Rhee, C.M., Cruz, S., Kashyap, M.L., Vaziri, N.D., Narayanaswami, V., Kalantar-Zadeh, K., Moradi, H. 2019. Association of Serum Paraoxonase/Arylesterase Activity With All-Cause Mortality in Maintenance Hemodialysis Patients, *The Journal of Clinical Endocrinology & Metabolism*, Volume 104, Issue 10, Pages 4848-4856, <https://doi.org/10.1210/jc.2019-00334>.
- Şükrü Ulusoy dan Gülsüm Özkan, 2013. Lipid Abnormalities in Hemodialysis Patients. *Hemodialysis.* IntechOpen. doi: 10.5772/52925.
- Sun, T., Hu, J., Yin, Z., Xu, Z., Zhang, L., Fan, L., Zhuo, Y., Wang, C. 2017. Low serum paraoxonase 1 activity levels predict coronary artery disease severity. *Oncotarget.* 8:19443-19454. <https://www.oncotarget.com/article/14305/text/>.
- Swain, R., Kaplan, B. 1995. Vitamins as therapy in the 1990s. *J Am Board Fam Prac.* 8: 206-16.
- Sztanek, F., Seres, I., Harangi, M., et al., 2012. Effect of nutritional status on human paraoxonase-1 activity in patients with chronic kidney disease. *Kidney Blood Press Res.* 36(1):310-319. doi: 10.1159/000343383.
- Tarnag, D.C., Huang, T.P. 1998. A parallel, comparative study of intravenous iron versus intravenous ascorbic acid for erythropoietin-hyporesponsive anaemia in haemodialysis patients with iron overload. *Nephrol Dial Transplant.* 13: 2867-2872 [PMID: 9829492].
- Tarnag, D.C., Wei, Y.H., Huang, T.P., Kuo, B.I., Yang, W.C. 1999. Intravenous ascorbic acid as an adjuvant therapy for recombinant erythropoietin in hemodialysis patients with hyperferritinemia. *Kidney Int.* 55:2477-2486. [PMID: 10354297].

- Tarnag, D.C., Liu, T.Y., Huang, T.P. 2004. Protective effect of vitamin C on 8-hydroxy-2'-deoxyguanosine level in peripheral blood lymphocytes of chronic hemodialysis patients. *Kidney Int.* 66: 820-831 [PMID: 15253739].
- Tessier, D.M., Khalil, A., Trottier, L., Fülöp, T. 2009. Effects of vitamin C supplementation on antioxidants and lipid peroxidation markers in elderly subjects with type 2 diabetes, *Archives of Gerontology and Geriatrics.* Vol. 48 (1):67-72, ISSN 0167-4943, <https://doi.org/10.1016/j.archger.2007.10.005>.
- Trentini, A., Bellini, T., Bonaccorsi, G., Cavicchio, C., Hanau, S., Passaro, A., Cervellati, C. 2019. Sex difference: an important issue to consider in epidemiological and clinical studies dealing with serum paraoxonase-1. *Journal of Clinical Biochemistry and Nutrition.* Vol. 64 (3): 250-256. ISSN 1880-5086. <https://doi.org/10.3164/jcbtn.1873>.
- Tsimihodimos, V., Dounousi, E. & Siamopoulos, K.C. 2008. Dyslipidemia in chronic kidney disease: an approach to pathogenesis and treatment. *Am. J. Nephrol.* 28:958-73.
- Tsimihodimos V, Mitrogianni Z, Elisaf M. 2011. Dyslipidemia associated with chronic kidney disease. *Open Cardiovasc Med J.* 5:41-8. doi: 10.2174/1874192401105010041. Epub. PMID: 21643500; PMCID: PMC3106357.
- Ueno, T., Doi, S., Nakashima, A., Yokoyama, Y., Doi, T., Kawai, T., Kusano, Y., Ueda, C., Masaki, T. 2015. The Serum Lipids Levels may be Underestimated in Patients on Hemodialysis, *Internal Medicine.* Vol. 54(8):887-894.
- Ulusoy, Sukru, and Gulsum Ozk. 2013. 'Lipid Abnormalities in Hemodialysis Patients'. *Hemodialysis. InTech.* doi:10.5772/52925.
- Vaziri, N.D. 2006. Dyslipidemia of chronic renal failure: the nature, mechanisms, and potential consequences. *Am. J. Physiol. Renal Physiol.* 290:262-72.
- Vitarius, J.A., Sultatos, L.G. 1995. The role of calcium in the hydrolysis of the organophosphate paraoxon by human serum A-esterase. *Life Sci.* 56(2):125-134.
- Wang, A.Y.M., Afsar, R.E., Sussman-Dabach, E.J., White, J.A., MacLaughlin, H., dan Ikizler, T.A. 2023. Vitamin Supplement Use in Patients With CKD: Worth the Pill Burden? *Am J Kidney Dis.* 83(3):370-385. Published online October 24, 2023. doi: 10.1053/j.ajkd.2023.09.005.
- Ward, R.A., McLeish, K.R., 2003. Oxidant stress in hemodialysis patients: what are the determining factors? *Artif Organs.* 27:230-6.
- Watanabe^a, J, Kotani K, Gugliucci A. 2023. Vitamin C supplementation and paraoxonase 1 activity in patients on hemodialysis: a meta-analysis. *Arch Med Sci Atheroscler Dis.* 11;8:e71-e74. doi: 10.5114/amsad/169981. PMID: 38089160; PMCID: PMC10711782.
- Watanabe^b, J, Kazuhiko, K., and Gugliucci, A. 2023. Paraoxonase 1 and Chronic Kidney Disease: A Meta-Analysis. *Journal of Clinical Medicine* 12, no. 3: 1199. <https://doi.org/10.3390/jcm12031199>.

- Watanabe^c, J., Kazuhiko, K., Yoshitaka, I., and Gugliucci, A. 2023. Paraoksonase 1 Activity and Renal Replacement Therapy for Chronic Renal Failure: A Meta-Analysis. *Journal of Clinical Medicine* 12, no. 15: 5123. <https://doi.org/10.3390/jcm12155123>.
- Wiemer, J., Winkler, K., Baumstark, M., März, W. & Scherberich, J.E. 2002. Influence of low molecular weight heparin compared to conventional heparin for anticoagulation during haemodialysis on low density lipoprotein subclasses. *Nephrol. Dial. Transplant.* 17:2231-8.
- Wikipedia Foundation, 2024. Vitamin C. Wikipedia [cited 2024 jun 26]. Available from: URL: https://en.wikipedia.org/wiki/Vitamin_C#.
- Wikipedia. 2025. Kt/V. Wikimedia Foundation, Inc. Available from: URL: <https://en.wikipedia.org/wiki/Kt/V#>.
- Xu, G.Y., Lv, G.C., Chen, Y., Hua, Y.C., Zhu, S.M., Yang, Y.D. 2005. Monitoring the level of serum paraoksonase 1 activity in liver transplantation patients. *Hepatobiliary Pancreat Dis Int.* 4(2):178-81. PMID: 15908311.
- Yang, C.-C., Hsu, S.-P., Wu, M.-S., Hsu, S.-M., Chien, C.-T. 2006. Effects of vitamin C infusion and vitamin E-coated membrane on hemodialysis-induced oxidative stress. *Kidney Int.* 69:706–714.
- Yang, W.L., Zhu, X.Y., Zhu, N., Su, C.Y., Han, Q.F., Wang, T., Zhang, A.H. 2016. What's the Optimal Lipids Level for Dialysis Patients? A Cohort Study from a Chinese Dialysis Center in a University Hospital. *PLoS One.* 11(12):e0167258. doi: 10.1371/journal.pone.0167258. PMID: 27992532; PMCID: PMC5161355.
- Yeun, J.Y., Kaysen, G.A. 1998. Factors influencing serum albumin in dialysis patients. *Am J Kidney Dis.* 32(6 Suppl 4):S118-25. doi: 10.1016/s0272-6386(98)70174-x. PMID: 9892378.
- Yousif, D. E., Xiaoling-Ye, Stuard, S., Berbessi, J., Guinsburg, A.M., Usvyat, L.A., et al. 2023. Biphasic Dynamics of Inflammatory Markers Following Hemodialysis Initiation: Results From the International Monitoring Dialysis Outcome Initiative. *Kidney International Reports.* Vol. 8 (Issue 1):75-80, ISSN 2468-0249, <https://doi.org/10.1016/j.ekir.2022.10.020>.
- Zhang, K., Dong, J., Cheng, X., Bai, W., Guo, W., Wu, L., Zuo, L. 2012. Association between Vitamin C deficiency and dialysis modalities. *Nephrology (Carlton).* 17:452-7.
- Zhang, K., Li, Y., Cheng, X., Liu, L., Bai, W., Guo, W., Wu, L., Zuo, L. 2013. Cross-over study of influence of oral vitamin C supplementation on inflammatory status in maintenance hemodialysis patients. *BMC Nephrol.* 14:252. doi: 10.1186/1471-2369-14-252].
- Zimmermann, J., Herrlinger, S., Pruy, A., Metzger, T., Wanner, C. 1999. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. *Kidney International.* Vol. 55 (2):648-658. ISSN 0085-2538. <https://doi.org/10.1046/j.1523-1755.1999.00273.x>.